Recipharm Wins SwedenBIO Award
The winner of the ninth annual SwedenBIO Award was announced on Thursday night (4th June). This year Recipharm AB was honoured for its efforts and contribution to Sweden life science during the past year.
The citation reads: "Recipharm has purposefully and with great skill built a solid organisation with a critical mass. A good revenue model has contributed to that the company created jobs in Sweden, but also established itself internationally. Recipharm is an extraordinary life science company that during the year strongly contributed to an increased interest in the industry and is an inspiring example for the whole of Swedish life science industry."
The prize is awarded to a company that demonstrated achievements and success beyond the norm in the life science industry in the past year and that has contributed to an increased interest in the business.
Lars Aldersson, Chairman of SwedenBIO said: “Recipharm shows that with the help of strong leadership, a responsible investment strategy and focus on quality it is possible to build a global life science company based in Sweden, something that will hopefully inspire others to similar deeds."
Thomas Eldered, CEO, commented: “We are very honoured to be recognized by SwedenBIO in this way. As an international company based in Sweden we are committed to investing and developing life science talent and capability here.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance